• November 11, 2011 - S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis
  • August 28, 2011 - Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification
  • July 14, 2011 - Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis
  • May 3, 2011 - Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation and Decrease Airspace Enlargement in Experimental Models of COPD
  • March 27, 2011 - Discovery of S-nitrosoglutathione reductase inhibitors as potential agents to treat asthma, COPD and IBD
More posters

January 24, 2013

Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
Qiumei Chen, Richard E. Sievers, Monika Varga, Sourabh Kharait, Daniel J. Haddad, Aaron K. Patton, Christopher S. Delany, Sarah C. Mutka, Joan P. Blonder, Gregory P. Dubé, Gary J. Rosenthal, and Matthew L. Springer

Nitric oxide (NO) exerts a wide range of cellular effects in the cardiovascular system. NO is short-lived, but S-nitrosoglutathione (GSNO) functions as a stable intracellular bioavailable NO pool. Accordingly, increased levels can facilitate NO-mediated processes, and conversely, catabolism of GSNO by the regulatory enzyme GSNO reductase (GSNOR) can impair these processes. Because dysregulated GSNOR can interfere with processes relevant to cardiovascular health, it follows that inhibition of GSNOR may be beneficial. However, the effect of GSNOR inhibition on vascular activity is unknown.

To study the effects of GSNOR inhibition on endothelial function, we treated rats with a small-molecule inhibitor of GSNOR (N6338) that has vasodilatory effects on isolated aortic rings and assessed effects on arterial flow-mediated dilation (FMD), an NO-dependent process. GSNOR inhibition with a single i.v. dose of N6338 preserved FMD (15.3±5.4% vs. 14.2±6.3%, P=NS) under partial NOS inhibition that normally reduces FMD by roughly 50% (14.1±2.9% vs.7.6±4.4%, P<0.05). In hypertensive rats, daily oral administration of N6338 for 14 days reduced blood pressure (170.0±5.3/122.7±6.4 mmHg vs. 203.8±1.9/143.7±7.5 mmHg for vehicle, P<0.001) and vascular resistance index (1.5±0.4 mmHg·min/L vs. 3.2±1.0 mmHg·min/L for vehicle, P<0.001), and restored FMD from an initially impaired state (7.4±1.7% day 0) to a level (13.0±3.1% day 14, P<0.001) similar to that observed in normotensive rats.

N6338 also reversed the pathological kidney changes exhibited by the hypertensive rats. GSNOR inhibition preserves FMD under conditions of impaired NO production and protects against both microvascular and conduit artery dysfunction in a model of hypertension.

(2013) Journal of Applied Physiology : doi:10.1152/japplphysiol.01302.2012 (More…JAP website – subscription required)

Comments are closed.